ClinicalTrials.gg
CompletedNCT02914548Updated Jul 23, 2020Results posted

Study of OPA-15406 Ointment in Patients With Atopic Dermatitis

A Phase 2 interventional study of OPA-15406 and Placebo in Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 3 sites in Japan. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-07-23.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
15 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.

Enrollment
7th of 16
200 · median 177
Started
2016
with 1 other
Phase 2
4 of 16
none open now
Registered
4th of 16
by date
Lead sponsor
9 of 16
Otsuka Pharmaceutical Co., Ltd.

Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 4th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difamilast

difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 15 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing difamilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
15 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of atopic dermatitis based on the criteria of Hanifin and Rajka

Exclusion criteria

Exclusion Criteria:

  • Subjects who have an atopic dermatitis or contact dermatitis flare-up defined as a sudden intensification of atopic dermatitis.
  • Subjects who have an active viral skin infection.
  • Subjects with a current or history of .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    0.3% OPA-15406

    Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.

    Drug: OPA-15406

  • Experimental
    1% OPA-15406

    Subjects were treated with assigned 1% OPA-15406 ointment twice daily.

    Drug: OPA-15406

  • Placebo comparator
    Placebo

    Subjects were treated with assigned 0% OPA-15406 ointment twice daily.

    Drug: Placebo

Interventions

  • Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.

  • DrugPlacebo

    Subjects were treated with assigned 0% OPA-15406 ointment twice daily.

06

What researchers measure

Primary outcomes

  1. Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4

    The investigator or sub investigator assessed the skin symptoms using IGA. The investigator or sub investigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week4. Incidence of success in IGA was defined as the rate of subjects whose IGA score was 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.

    Time frame: At Week 4

Secondary outcomes

  1. Change From Baseline in Eczema Area and Severity Index (EASI) Score

    The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs). Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.

    Time frame: Baseline, Week 4

  2. Change From Baseline in Visual Analogue Scale(VAS) for Pruritus Score

    The investigator or subinvestigator evaluated the level of pruritus based on VAS. The subjects will mark the point of pruritus intensity during the last 24 hours on the line of a 100- mm VAS sheet between the left end (no pruritus: the score is 0 ) and the right end (very severe pruritus: the score is 100), and a negative change from the baseline means improvement and a positive change means worsening. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded

    Time frame: Baseline, Week 4

  3. Change From Baseline in Verbal Rating Scale(VRS) for Pruritus Score

    The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects aged 7 to 14 years old evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary. 0 : None 1. : Mild 2. : Moderate 3. : Severe For subjects aged 2 to 6 years, this would not be evaluated. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.

    Time frame: Baseline, Hour 156

  4. Change From Baseline in Patient-Oriented Eczema Measure(POEM) Score

    The investigator or sub investigator evaluated eczema according to the POEM. The subjects answered 7 questions about their eczema by 0-4 points per question. The POEMS's minimum and maximum scores are 0 and 28 scores respectively. The higher the POEM score is, the more severe the symptoms are, and a negative change from the baseline means improvement and a positive change means worsening. If it is difficult for subjects to answer the questions, their parents answered them instead. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.

    Time frame: Baseline, Week 4

  5. Change From Baseline in Percentage Affected Body Surface Area

    The investigator or subinvestigator drew the affected BSA (range of skin eruption at the time of examination) on the human body drawing to determine the affected areas (%) on the respective 4 body regions (face, neck, and head; upper limbs; trunk; and lower limbs). One palm of the subject corresponds to 1% BSA.

    Time frame: Baseline, Week 4

  6. Mean (SD) OPA-15406 Plasma Trough Concentrations

    The plasma concentration of OPA-15406 was measured at Week1, Week4 and Week8. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration. Number of participants analyzed represents number of participants with data at each point. Participants who have no effective data were excluded.

    Time frame: Week1, Week4, Week8

  7. Mean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA

    The plasma concentration of OPA-15406 was measured at Week1, Week4 and Week8. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.Number of participants analyzed represents number of participants with data at each point. Participants who have no effective data were excluded.

    Time frame: Week1, Week4, Week8

  8. OPA-15406 Plasma PK Parameters, Cmax

    OPA-15406 plasma PK parameter (Cmax) was measured on Day 1 and at Week 4 following topical administration of OPA-15406 0.3% and 1% ointment to adult subjects with AD.Number of participants analyzed represents number of participants with effective data at each point. Participants who have no effective data were excluded.

    Time frame: Day 1 and Week 4

  9. OPA-15406 Plasma PK Parameters, AUC8h

    OPA-15406 plasma PK parameter (AUC8h) was measured on Day 1 and at Week 4 following topical administration of OPA-15406 0.3% and 1% ointment to adult subjects with AD.Number of participants analyzed represents number of participants with effective data at each point. Participants who have no effective data were excluded.

    Time frame: Day 1 and Week 4

07

Results

Posted Jun 29, 2020

Participant flow

Participant flow — Overall Study
Milestone0.3% OPA-154061% OPA-15406Placebo
Started676766
Completed465346
Not completed211420
Withdrew: Adverse event15715
Withdrew: Physician decision220
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject344
Withdrew: >40% of body surface area011

Outcome measures

PrimaryResponder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4

The investigator or sub investigator assessed the skin symptoms using IGA. The investigator or sub investigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week4. Incidence of success in IGA was defined as the rate of subjects whose IGA score was 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.

Time frame:
At Week 4
Reported as:
Number · percentage of participants
Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4
percentage of participants0.3% OPA-154061% OPA-15406Placebo
Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week414.93 (7.40 to 25.74)22.39 (13.11 to 34.22)9.09 (3.41 to 18.74)
SecondaryChange From Baseline in Eczema Area and Severity Index (EASI) Score

The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs). Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.

Time frame:
Baseline, Week 4
Reported as:
Mean · score on a scale
Change From Baseline in Eczema Area and Severity Index (EASI) Score
score on a scale0.3% OPA-154061% OPA-15406Placebo
Change From Baseline in Eczema Area and Severity Index (EASI) Score-2.32 ± 0.75-3.16 ± 0.75-0.15 ± 0.77
SecondaryChange From Baseline in Visual Analogue Scale(VAS) for Pruritus Score

The investigator or subinvestigator evaluated the level of pruritus based on VAS. The subjects will mark the point of pruritus intensity during the last 24 hours on the line of a 100- mm VAS sheet between the left end (no pruritus: the score is 0 ) and the right end (very severe pruritus: the score is 100), and a negative change from the baseline means improvement and a positive change means worsening. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded

Time frame:
Baseline, Week 4
Reported as:
Mean · mm
Change From Baseline in Visual Analogue Scale(VAS) for Pruritus Score
mm0.3% OPA-154061% OPA-15406Placebo
Change From Baseline in Visual Analogue Scale(VAS) for Pruritus Score-6.76 ± 3.31-6.28 ± 3.320.90 ± 3.24
SecondaryChange From Baseline in Verbal Rating Scale(VRS) for Pruritus Score

The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects aged 7 to 14 years old evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary. 0 : None 1. : Mild 2. : Moderate 3. : Severe For subjects aged 2 to 6 years, this would not be evaluated. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.

Time frame:
Baseline, Hour 156
Reported as:
Mean · score on a scale
Change From Baseline in Verbal Rating Scale(VRS) for Pruritus Score
score on a scale0.3% OPA-154061% OPA-15406Placebo
Change From Baseline in Verbal Rating Scale(VRS) for Pruritus Score-0.43 ± 0.10-0.49 ± 0.10-0.06 ± 0.10
SecondaryChange From Baseline in Patient-Oriented Eczema Measure(POEM) Score

The investigator or sub investigator evaluated eczema according to the POEM. The subjects answered 7 questions about their eczema by 0-4 points per question. The POEMS's minimum and maximum scores are 0 and 28 scores respectively. The higher the POEM score is, the more severe the symptoms are, and a negative change from the baseline means improvement and a positive change means worsening. If it is difficult for subjects to answer the questions, their parents answered them instead. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.

Time frame:
Baseline, Week 4
Reported as:
Mean · score on a scale
Change From Baseline in Patient-Oriented Eczema Measure(POEM) Score
score on a scale0.3% OPA-154061% OPA-15406Placebo
Change From Baseline in Patient-Oriented Eczema Measure(POEM) Score-1.36 ± 0.77-2.90 ± 0.76-0.02 ± 0.79
SecondaryChange From Baseline in Percentage Affected Body Surface Area

The investigator or subinvestigator drew the affected BSA (range of skin eruption at the time of examination) on the human body drawing to determine the affected areas (%) on the respective 4 body regions (face, neck, and head; upper limbs; trunk; and lower limbs). One palm of the subject corresponds to 1% BSA.

Time frame:
Baseline, Week 4
Reported as:
Mean · percentage of Affected Body Surface Area
Change From Baseline in Percentage Affected Body Surface Area
percentage of Affected Body Surface Area0.3% OPA-154061% OPA-15406Placebo
Change From Baseline in Percentage Affected Body Surface Area-3.94 ± 1.44-3.73 ± 1.43-0.32 ± 1.48
SecondaryMean (SD) OPA-15406 Plasma Trough Concentrations

The plasma concentration of OPA-15406 was measured at Week1, Week4 and Week8. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration. Number of participants analyzed represents number of participants with data at each point. Participants who have no effective data were excluded.

Time frame:
Week1, Week4, Week8
Reported as:
Mean · ng/mL/mg
Mean (SD) OPA-15406 Plasma Trough Concentrations
ng/mL/mg0.3% OPA-154061% OPA-15406
Week 11.74 ± 1.874.96 ± 5.04
Week 41.71 ± 2.505.22 ± 4.70
Week 81.51 ± 1.775.52 ± 8.28
SecondaryMean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA

The plasma concentration of OPA-15406 was measured at Week1, Week4 and Week8. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.Number of participants analyzed represents number of participants with data at each point. Participants who have no effective data were excluded.

Time frame:
Week1, Week4, Week8
Reported as:
Mean · ng/mL/mg
Mean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA
ng/mL/mg0.3% OPA-154061% OPA-15406
Week 10.114 ± 0.09910.113 ± 0.0952
Week 40.104 ± 0.1190.127 ± 0.119
Week 80.0910 ± 0.1030.137 ± 0.242
SecondaryOPA-15406 Plasma PK Parameters, Cmax

OPA-15406 plasma PK parameter (Cmax) was measured on Day 1 and at Week 4 following topical administration of OPA-15406 0.3% and 1% ointment to adult subjects with AD.Number of participants analyzed represents number of participants with effective data at each point. Participants who have no effective data were excluded.

Time frame:
Day 1 and Week 4
Reported as:
Mean · ng/mL
OPA-15406 Plasma PK Parameters, Cmax
ng/mL0.3% OPA-154061% OPA-15406
Day 14.01 ± 5.907.27 ± 6.42
Week 42.07 ± 1.4710.4 ± 3.68
SecondaryOPA-15406 Plasma PK Parameters, AUC8h

OPA-15406 plasma PK parameter (AUC8h) was measured on Day 1 and at Week 4 following topical administration of OPA-15406 0.3% and 1% ointment to adult subjects with AD.Number of participants analyzed represents number of participants with effective data at each point. Participants who have no effective data were excluded.

Time frame:
Day 1 and Week 4
Reported as:
Mean · ng・h/mL
OPA-15406 Plasma PK Parameters, AUC8h
ng・h/mL0.3% OPA-154061% OPA-15406
Day 122.0 ± 34.741.6 ± 37.6
Week 411.6 ± 7.2365.2 ± 26.8

Adverse events

Collected over Treatment period (8 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.3% OPA-154060/67 (0%)0/67 (0%)22/67 (32.8%)
1% OPA-154060/67 (0%)0/67 (0%)11/67 (16.4%)
Placebo0/66 (0%)0/66 (0%)20/66 (30.3%)
Most frequent other events
Most frequent other events
Event0.3% OPA-154061% OPA-15406Placebo
Dermatitis atopicSkin and subcutaneous tissue disorders11/676/6712/66
Viral upper respiratory tract infectionInfections and infestations7/674/677/66
PruritusSkin and subcutaneous tissue disorders5/671/674/66

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)0.3% OPA-154061% OPA-15406PlaceboTotal
<=18 years2013
Between 18 and 65 years656765197
>=65 years0000
Age, Continuous
Age, Continuous(years)0.3% OPA-154061% OPA-15406PlaceboTotal
Mean30.2 ± 9.031.0 ± 10.831.6 ± 10.030.9 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)0.3% OPA-154061% OPA-15406PlaceboTotal
Female22252370
Male454243130
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)0.3% OPA-154061% OPA-15406PlaceboTotal
Japanese676766200
Region of Enrollment
Region of Enrollment(Participants)0.3% OPA-154061% OPA-15406PlaceboTotal
Japan676766200
08

Study locations

3 sites
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kiniki Region, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jun 2017, 9 months.

Results were first posted in Jun 2020, 3 years after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 9 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2016
First posted
Sep 26, 2016
StartActual
Sep 2016
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Results first posted
Jun 29, 2020
Last update
Jul 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02914548
Responsible party
Sponsor
First posted
Sep 26, 2016
Start date
Sep 2016
Primary completion
Jun 2017
Completion
Jun 2017
Results posted
Jun 29, 2020
Last update
Jul 23, 2020

Study contacts

Hiroaki Ono, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difamilast

Start the discussion